XML 59 R43.htm IDEA: XBRL DOCUMENT v3.25.0.1

FAIR VALUE MEASUREMENTS (Tables)

12 Months Ended

Dec. 31, 2024

Fair Value Disclosures [Abstract]

Schedule of fair value measurements along with the level within the fair value hierarchy in which the fair value measurements fall

The following table presents the Company’s fair value measurements as of December 31, 2024 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall.

(In thousands)						Fair value at December 31, 2024						Quoted Prices in Active Markets for Identical Assets (Level 1)						Significant Other Observable Inputs (Level 2)						Significant Unobservable Inputs (Level 3)
Cash, cash equivalents, and restricted cash
Cash and money market						$	595,548					$	595,548					$	—					$	—
Restricted cash (1)						5,747						5,747						—						—
U.S. government agency securities						5,341						—						5,341						—
Marketable securities
Corporate bonds						$	206,874					$	—					$	206,874					$	—
U.S. government agency securities						140,952						—						140,952						—
Asset backed securities						83,339						—						83,339						—
Equity securities						5,972						5,972						—						—
Non-marketable securities						$	796					$	—					$	—					$	796
Liabilities
Contingent consideration						$	(282,212)					$	—					$	—					$	(282,212)
Total						$	762,357					$	607,267					$	436,506					$	(281,416)

The following table presents the Company’s fair value measurements as of December 31, 2023 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall.

(In thousands)						Fair Value at December 31, 2023						Quoted Prices in Active Markets for Identical Assets (Level 1)						Significant Other Observable Inputs (Level 2)						Significant Unobservable Inputs (Level 3)
Cash, cash equivalents, and restricted cash
Cash and money market						$	530,100					$	530,100					$	—					$	—
Commercial paper						72,243						—						72,243						—
Restricted cash (1)						4,297						4,297						—						—
U.S. government agency securities						3,035						—						3,035						—
Marketable securities
U.S. government agency securities						$	56,716					$	—					$	56,716					$	—
Corporate bonds						55,828						—						55,828						—
Asset backed securities						34,897						—						34,897						—
Commercial paper						20,984						—						20,984						—
Equity securities						3,841						3,841						—						—
Non-marketable securities						$	7,650					$	—					$	—					$	7,650
Liabilities
Contingent consideration						$	(288,657)					$	—					$	—					$	(288,657)
Total						$	500,934					$	538,238					$	243,703					$	(281,007)

_________________________________

(1)Restricted cash primarily represents cash held by a third-party financial institution as part of a cash collateral agreement related to the Company’s credit card program. The restrictions will lapse upon the termination of the agreements or the removal of the cash collateral requirement by the third-parties.

Schedule of fair value of contingent consideration

The following table provides a reconciliation of the beginning and ending balances of contingent consideration:

						Year Ended December 31,
(In thousands)						2024						2023						2022
Beginning balance						$	288,657					$	306,927					$	359,021
Purchase price contingent consideration (1)						—						—						4,600
Changes in fair value (2)						(3,345)						(18,044)						(56,617)
Payments (3)						(3,100)						(226)						(77)
Ending balance						$	282,212					$	288,657					$	306,927

_________________________________

(1)    The increase in contingent consideration liability is due to the contingent consideration associated with the acquisition of OmicEra. Refer to Note 18 for further information.

(2)    The change in fair value of the contingent consideration liability is included in general and administrative expenses in the consolidated statement of operations for the years ended December 31, 2024, 2023, and 2022.

(3)    Payment was made in the second quarter of 2024 to settle the contingent consideration liability previously recorded related to the Company’s acquisition of OmicEra.

Other Investments Not Readily Marketable

Non-Marketable Equity Securities

Non-marketable equity securities without readily determinable fair values, which are classified as a component of other long-term assets, net, had the following cumulative upward and downward adjustments and aggregate carrying amounts:

						Year Ended December 31,
(In thousands)						2024						2023
Cumulative upward adjustments (1)						$	5,102					$	5,093
Cumulative downward adjustments and impairments (2)						(16,850)						(15,071)
Aggregate carrying value						50,448						45,968

_________________________________

(1)    There were no material upward adjustments recorded on non-marketable equity securities held for the years ended December 31, 2024, 2023, and 2022.

(2)    There were no material downward adjustments or impairments on non-marketable equity securities held for the years ended December 31, 2024, 2023, and 2022.

Securities Owned Not Readily Marketable

The Company has elected the fair value option under the income approach to measure certain Level 3 non-marketable securities. The following table provides a reconciliation of the beginning and ending balances of non-marketable securities valued using the fair value option:

(In thousands)						Non-Marketable Securities
Balance, January 1, 2023						$	10,065
Purchases of non-marketable securities						6,957
Changes in fair value						1,127
Settlement of non-marketable securities						(10,499)
Balance, December 31, 2023						7,650
Changes in fair value						(604)
Settlement of non-marketable securities						(6,250)
Balance, December 31, 2024						$	796

X

- Definition

Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

+ Details

Name:	us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_FairValueDisclosuresAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of other investments not readily marketable, including, but not limited to, description of investment, fair value and value as measured by quoted price.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

+ Details

Name:	us-gaap_ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of not readily marketable securities and investments including, but not limited to, description of security or investment, fair value and value as measured by quoted price.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

+ Details

Name:	us-gaap_ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration